Please assess the completion status of the following clinical trial:

Trial Title: HSK7653 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 and ≤ 75 years, Male and female patients;~* Type 2 diabetes mellitus;~* Control the blood glucose level only with diet and exercise in last 8 weeks;~* Did not receive regular long-term medication of oral hypoglycemic drugs or insulin within 1 year prior to informed consent;~* HbA1c in the range of ≥7.5 to ≤11.0% at screening;~* FPG \< 15 mmol/L at screening;~* BMI (Body Mass Index) in the range of ≥ 18.0 kg/m² to ≤ 35.0 kg/m² at screening.~Exclusion Criteria:~* Diabetic ketoacidosis, hyperglycemia hypertonic state, serious complications of diabetes, myocardial infarction, stroke within 6 months prior to informed consent;~* History of severe endocrine disease, uncured cancer, acute pancreatitis prior to informed consent;~* Current hemoglobinopathy, uncontrolled hypertension, serious nephropathy or hepatopathy prior to informed consent;~* Serious gastrointestinal disease within 2 weeks prior to informed consent;~* Serious infection, trauma and surgery within 3 months prior to informed consent;~* History of treatment with Dipeptidyl-Peptidase 4 (DPP-4) inhibitor, Glucose-dependent insulinotropic polypeptide (GIP) or Glucagon-like peptide-1 (GLP-1) receptor agonist;~* Treatment with drugs that affect glucose metabolism within 8 weeks prior to informed consent;~* Hemoglobin (HGB) \< 10.0 g/dL(100 g/L);~* Alcohol abuse within 6 months or drug abuse history within 5 years prior to informed consent;~* Active infectious diseases;~* Participation in another trial with an investigational drug or instrument within 3 months prior to informed consent;~* Women who are nursing or pregnant, or subjects with birth plans;~* Contraindication for metformin;~* Other protocol-defined inclusion/exclusion criteria.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- HSK7653 10 mg (Type: EXPERIMENTAL): None
- HSK7653 25 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).